54226-20-9Relevant academic research and scientific papers
Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics
Charrier, Nicolas,Clarke, Brian,Cutler, Leanne,Demont, Emmanuel,Dingwall, Colin,Dunsdon, Rachel,Hawkins, Julie,Howes, Colin,Hubbard, Julia,Hussain, Ishrut,Maile, Graham,Matico, Rosalie,Mosley, Julie,Naylor, Alan,O'Brien, Alistair,Redshaw, Sally,Rowland, Paul,Soleil, Virginie,Smith, Kathrine J.,Sweitzer, Sharon,Theobald, Pam,Vesey, David,Walter, Daryl S.,Wayne, Gareth
scheme or table, p. 3664 - 3668 (2010/03/24)
Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. We have recently disclosed a series of transition-state mimetic BACE-1 inhibitors showing nanomolar potency in cell-based assays.
HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Page 57, (2010/02/07)
The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.
